SEC Comment Letter for KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA) — Jul 24, 2018
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: July 24, 2018 · CIK: 0001075880 · Accession: 0000000000-18-022699
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226240
Letter
July 24, 2018 James Garner Chief Executive Officer Kazia Therapeutics Limited Level 24, Three International Towers 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-3 Filed July 19, 2018 File No. 333-226240 Dear Mr. Garner: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form F-3 Incorporation By Reference, page 29 1.Please incorporate by reference the description of the securities being registered contained in a registration statement filed under Section 12 of the Exchange Act as required by Item 6(a) of Form F-3. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameJames Garner Comapany NameKazia Therapeutics Limited July 24, 2018 Page 2 FirstName LastName James Garner Kazia Therapeutics Limited July 24, 2018 Page 2 Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Ada D. Sarmento at 202-551-3798 or Irene Paik at 202-551-6553 with any other questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Andrew Reilly, Esq.
Show Raw Text
July 24, 2018
James Garner
Chief Executive Officer
Kazia Therapeutics Limited
Level 24, Three International Towers
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-3
Filed July 19, 2018
File No. 333-226240
Dear Mr. Garner:
We have limited our review of your registration statement to those issues we have
addressed in our comments. In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form F-3
Incorporation By Reference, page 29
1.Please incorporate by reference the description of the securities being registered contained
in a registration statement filed under Section 12 of the Exchange Act as required by Item
6(a) of Form F-3.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameJames Garner
Comapany NameKazia Therapeutics Limited
July 24, 2018 Page 2
FirstName LastName
James Garner
Kazia Therapeutics Limited
July 24, 2018
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Ada D. Sarmento at 202-551-3798 or Irene Paik at 202-551-6553 with any
other questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Andrew Reilly, Esq.